The clinical trials in NB patients have demonstrated that 43% or more of patients had ADA reactions against 14.G2a [9, 37], 19–21% against ch14.18 [38], and 40% against humanized antibody hu14.18K322A [16]. Here, ADA is linked to neuroblastoma.